New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed advanced leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, or angiosarcoma with 1-2 prior chemotherapy : neoadjuvnat or adjuvant chemotherapy is counted as one regimen 2. Age ≥19 years, \<80 years 3. ECOG performance status of 0-1 4. Has at least 1 measurable lesion (as defined by RECIST v1.1). 5. Has adequate organ function defined by the following criteria: * Hb ≥ 9.0 g/dL * Absolute neutrophil count (ANC) ≥ 1500 /µL * Platelet ≥ 75,000/ µL * Total Bilirubin: ≤ 1.5 × UNL (upper normal limit) (≤ 2 × UNL in patients with liver metastasis) * Serum Creatinine: ≥ 50 mL/min * AST(SGOT)/ALT(SGPT): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver metastasis) * Alkaline Phosphatase (ALP): ≤ 3.0 × UNL or ≤ 5.0 × UNL (in patients with liver or bone metastasis) 6. Female patient of childbearing potential has a negative serum or urine pregnancy test for β-hCG 7. Able to provide written informed consent and comply with the protocol requirements Exclusion Criteria: 1. Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to entering the study 2. More than 3 prior cytotoxic agents 3. previously received treatment with bevacizumab, gemcitabine, or docetaxel 4. Unresolved toxicities from prior anticancer therapy ≥ Grade 2 according to NCI CTCAE, excluding alopecia, vitiligo, and laboratory abnormalities defined in the inclusion criteria 5. Major surgery within 28 days prior to randomization. 6. Active or prior documented autoimmune or inflammatory disorders 7. Unstable cardiovascular disease 8. Has an active infection requiring parenteral treatment 9. History of another primary malignancy 10. Uncontrolled or active CNS metastasis and/or carcinomatous meningitis 11. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study 12. Pre-existing interstitial lung disease (ILD)